| ADTX 0.01 127.27% | GDC 0.0181 -15.02% | SOXS 3.59 -19.51% | GPUS 0.359 -9.78% | SRXH 0.1245 -37.59% | BITO 8.56 -1.95% | TZA 4.02 -5.85% | SPCX 185 -3.56% | MRVL 310.58 7.27% | CDT 1.02 47.19% | NVDA 210.69 2.95% | INTC 133.99 10.64% | WKSP 0.7379 23.33% | INLF 0.1566 -64.20% | NOK 13.49 -2.46% | AAL 15.99 3.70% | AZTR 0.1717 -15.42% | CAST 8.07 56.70% | CRVO 4.24 11.29% | NFLX 77.38 0.55% | AMC 2.83 6.39% | QS 8.04 16.52% | FLEX 147.61 3.13% | GRAB 3.57 3.48% | SOFI 17.91 2.81% | YYGH 0.0803 -37.70% | AAPL 298.01 0.70% | ATPC 3.88 42.12% | RKLB 107.24 -0.69% | BAC 56.2 -0.58% | LNKS 2.68 67.50% | SMCI 30.66 10.37% | PFE 25.22 -2.70% | SPY 746.74 0.78% | RIG 5.31 -4.84% | AMZN 244.39 2.90% | PLUG 2.85 7.55% | CRWV 117.95 2.38% | TSLL 13.16 1.86% | ONDS 9.27 1.64% | CMCSA 22.43 -1.15% | MU 1133.99 8.70% | TQQQ 82.87 6.87% | BFLY 8.9 55.87% | NVD 4.75 -5.57% | SQQQ 36.75 -7.01% | MSFT 379.4 0.13% | CTSH 43.7 -10.49% | WPRT 2.26 21.51% | T 22.01 -1.92%

Hyperfine, Inc. (NASDAQ: HYPR) Surpasses EPS Estimates with Its Latest Earnings Report

Hyperfine, Inc. (NASDAQ:HYPR), a leading name in the health technology sector, is celebrated for its innovative Swoop® system, the first FDA-cleared AI-powered portable MR brain imaging system. The company has recently introduced its second-generation Swoop® scanner and Optive AI™ software, marking a significant leap forward in medical imaging technology. Hyperfine is venturing into the neurology office market, aiming to extend its influence and impact in healthcare.

On March 18, 2026, HYPR disclosed its earnings, revealing an earnings per share (EPS) of -$0.06, surpassing the estimated EPS of -$0.08. This demonstrates that the company's performance exceeded expectations, despite the negative EPS. The revenue for the period was approximately $5.29 million, slightly below the estimated $5.3 million, indicating a minor shortfall in sales expectations.

The company's financial metrics present a mixed outlook. With a price-to-sales ratio of approximately 7.13, investors are paying over seven times the company's sales for its stock, reflecting high investor confidence. However, the enterprise value to sales ratio of about 4.55 suggests a more conservative valuation when considering debt and cash, indicating a balanced view of the company's financial health.

HYPR's current ratio of 4.34 underscores a strong liquidity position, as it has more than four times the current assets compared to its current liabilities. This suggests that the company is well-equipped to meet its short-term obligations. However, the negative earnings yield and price-to-earnings ratio signal financial challenges, possibly due to ongoing investments in technology and market expansion.

Despite these hurdles, Hyperfine's strategic initiatives, such as the launch of its second-generation Swoop® scanner and expansion into new markets, are poised to fuel growth. As highlighted by Seeking Alpha, the company's proprietary technology and commitment to innovation position it favorably for future success, potentially accelerating the adoption of the Swoop® system across various healthcare settings.

Published on: March 19, 2026